Smart Biopsy System
Dilon Devices was selected as one of the few recipients of the European Union Horizon 2020 research grant to spur development of our biopsy system. This new product will expand our surgical oncology portfolio to include a soft tissue biopsy system with its first indication in breast tissue.
This project has received funding from the European Union’s Horizon 2020 research and innovation program.
We are implementing a go-to-market strategy expanding into new countries. To lead this initiative an 18-month study is being conducted across the U.K. and will look at the health, cosmetic and financial impact of MarginProbe® for lumpectomy patients.
Exploring New Indications
Margins matter in many cancer indications. MarginProbe® was initially FDA approved for breast cancer patients and we are now looking to expand our ground breaking technology into additional indications such as prostate, colon, lung and pancreas.
View the study by clicking here.